VIDO’s COVID-19 vaccine receives Health Canada clinical trial approval

VIDO’s COVID-19 vaccine receives Health Canada clinical trial approval for subunit-based vaccine combined to the open-access adjuvant Sepivac SWE, that was developed by Seppic in collaboration with VFI. First-in-human trials are planned in January 2021. Click here for press release.